unreliable for the estimation of GFR. The patients most often collected the 24 hour urine on an outpatient basis, and we believe that these unsatisfactory results can be caused by imprecise urine collection.
It is evident from the present study and the above mentioned reports that the combination regimens of platinum and podophyllin derivatives can produce high response rates in the treatment of extensive SCLC, but it is rather disappointing that response duration and survival time remain very short. A possible step forward could be dose intensification combined with haematopoietic growth factors. 
INTRODUCTION PATIENTS AND METHODS
THE OUTLOOK for patients with adenocarcinoma of the oesophagus is dismal; in about 40% metastatic disease is apparent at first presentation. Even if a patient is operable, the 5-year survival after surgery with curative intent is < 10%. Most of these patients die with distant metastases. Obviously, there is a need for effective chemotherapy. We investigated the activity and toxicity of ifosfamide.
Until July 1990,25 consecutive previously untreated patients were entered in the study. The main eligibility criteria were histologically proven adenocarcinoma of the oesophagus or oesophageal-gastric junction area, with or without Barrett's epithelium (patients with adenocarcinoma of the gastric cardia, without involvement of the oesophageal-gastric junction area were not eligible); performance status (Karnofsky) > 60% and a life expectancy of 3 months or more; age 75 years or less; no prior chemotherapy; no symptomatic brain metastases; adequate bone marrow and kidney function (clearance > 60 mumin); measurable disease-if the primary tumour was the only marker lesion and not previously irradiated, the disease was considered evaluable and monitored by barium radiogram, computed tomography and endoscopy with biopsies; and a guaranteed food intake (in cases of severe stenosis, a prosthetic intubation was performed). Patients with a probability of < 0.05 of not developing severe CNS toxicity after ifosfamide/mesna infusion, calculated by means of serum albumin and creatinine concentration according to the monogram described by Meanwell et al.
[l], were not eligible. Treatment consisted of prehydration with 500 ml saline 0.9% for 2 h followed by 200 ml mannitol20% over 30 min and mesna 1 g/m2 intravenously. Ifosfamide was given as a 48 h infusion in a total dose of 6 g/m2 together with 6000 ml dextrose/saline and mesna 3 g/m2. Posthydration was given with 2500 ml dextrose/saline over 16 h together with mesna 2 g/m'. Courses were repeated every 4 weeks. Patients were evaluable for response after two courses, and evaluable for toxicity after one course. In cases of clear progression after the first course, the response was evaluated as early progression. In cases of stable disease after any two cycles, treatment was stopped. The maximal duration of treatment was six cycles or until progression of disease or intolerable toxicity, physical or mental. The recommended guidelines for the criteria of evaluation and toxic effects proposed by the WHO (1979) [2] were followed. Blood counts were performed weekly.
Of 25 entered patients, 1 was not eligible (adenocarcinoma of the gastric cardia without involvement of the oesophagealgastric junction area) and 1 was not evaluable for response Table 1 ; tumour characteristics are shown in Table 2 . Most patients were men with a fair performance status, notwithstanding a significant weight loss, who had metastatic cancer at first presentation.
Toxicity data of 24 patients are shown in Table 3 , graded according to WHO criteria (1979) . Of a total of 63 courses, the median number was only two. There was no treatment delay because of cytopenia; only once did a leucocyte nadir of 1.1 in combination with fever require a dose reduction of 25% for the next courses. In 2 cases a serious infection (WHO grade 3) required hospital admission for intravenous antibiotic therapy (WBC nadir 1.7 and 1.1 x 109/1). No serious renal toxicity nor any CNS toxicity were seen during the study. Reasons for going off study were: serious subjective toxicity (n = l), progressive disease during treatment (ll), stable disease after two courses (7) and end of protocol treatment (4). 1 patient experienced rapid deterioration of his condition after the first course: no response evaluation was done.
Among 23 patients evaluable for response, 1 achieved a complete response (CR: response duration 29+ months) and 1 a partial response (PR: response duration 7 months).
The patient who achieved a CR was a 47-year-old man, with a poorly differentiated adenocarcinoma in Barrett's epithelium and microscopically proven metastatic lymph-nodes in the coeliac region at laparotomy. He refused surgical treatment after six courses of chemotherapy, and is now, 24 years later, in perfect condition without clinically detectable tumour (endoscopy plus biopsies). The median survival time of all evaluable patients was 7 months (range 2-54) after start of treatment and 3.5 months after stopping chemotherapy. 3 patients are still alive, with a follow-up of 2, 3 and 24 + months, respectively, after stopping treatment.
ing the dose and schedule of ifosfamide, we administered 6 g/m* as a continuous infusion over 48 h instead of 7.5 g/m2 over 5 days as daily short intravenous infusions. On the other hand, our data on bone marrow suppression are not different from those of Ansell et al., and clearly less serious than those of Nanus et al., who experienced 18 episodes of WBC count nadir < 1000 in 59 cycles of therapy against 0 in our series of 63 cycles.
DISCUSSION
Although 2 patients in this phase II study achieved a well documented major regression, ifosfamide seems to have minor activity in untreated patients with advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Such a lack of response has also been documented for epidermoid carcinoma of the oesophagus in two other trials [ 3, 41. However, we could not confirm the severe toxicity, especially myelosuppression, described in these reports. Several factors could play a role in this discrepancy. For example, our patients had a better performance status than those described by Ansell et al. [3] . More than half of the patients in Nanus et aZ.'s report were pretreated with radiotherapy and/or chemotherapy [4] . ConcernIn conclusion, ifosfamide, given in a dose of 6 g/m2 over 48 h, has a low activity as first-line treatment in patients with adenocarcinoma of the oesophagus. The application of a continuous administration over 48 h may result in a more favourable toxicity profile than observed in fractionated regimens using daily short intravenous infusions for several days. Adjuvant immunochemotherapy using the antitumour polysaccharide sizofiran (SPG), an extract from the culture broth of Schizophyllum commune Fries, was prescribed randomly for 386 Japanese patients with resectable gastric cancer. Although the overall survival probability for 5 years did not differ between the SPG and control groups, in 264 patients with curatively resected cancer, the probability to 5 year survival and to recurrence in the sizolkan-administered patients was better than in the controls. In the multivariate analysis, four of six prognostic factors correlated with the prognosis of the 264 patients who underwent curative surgery, that is, nodal involvement (x2 = 21.426, P = < O.OOOl), age distribution (x2 = 9.262, P = O.OlO), sizofiran administration (x2 = 6.507, P = O.Oll), and primary tumour size (x2 = 9.345, P = 0.025). Thus, patients with a curatively resected gastric cancer had a better prognosis when sizofiran was prescribed in combination with antitumour drugs. EurJ Cancer, Vol. 27, No. 9, pp. 1114 -1118 .
INTRODUCTION recurrence has to be given due consideration. For this purpose, WHILE AN early diagnosis of gastric cancer is now feasible, adjuvant cancer chemotherapy has been prescribed [l-3] , but extensive resection has to be done for those in the advanced since anticancer drugs have immunosuppressive effects, adjustage of the disease. The long-term survival of these patients vant immunotherapy is required to gain an extended time of depends on the extent of micrometastasis present at the time survival. of surgery, that is, the micrometastasis responsible for the Sizofiran (SPG), a glucan extracted from culture medium
